SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-069993
Filing Date
2023-06-09
Accepted
2023-06-09 17:11:26
Documents
12
Period of Report
2023-06-09
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2318324d1_8k.htm   iXBRL 8-K 22291
  Complete submission text file 0001104659-23-069993.txt   195025

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tbph-20230609.xsd EX-101.SCH 3039
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tbph-20230609_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tbph-20230609_pre.xml EX-101.PRE 22599
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2318324d1_8k_htm.xml XML 3621
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36033 | Film No.: 231006285
SIC: 2834 Pharmaceutical Preparations